Angion Biomedica Corp. To Present Clinical And Preclinical Data At The Upcoming American Society of Nephrology Conference In San Diego
UNIONDALE, N.Y.--(BUSINESS WIRE)--Angion Biomedica Corp. announced today that it will present Phase 2 data from one clinical program and three preclinical programs at the American Society of Nephrology Kidney Week, November 3-8, 2015 in San Diego, CA.
Two presentations are scheduled on Angion’s clinical stage investigational drug BB3, a proprietary small molecule with hepatocyte growth factor (HGF)-like therapeutic activities. In a presentation entitled “BB3, a Hepatocyte Growth Factor-like Small Molecule, Improves Outcome in Kidney Transplant Recipients with Delayed Graft Function," data from an interim analysis of a double-blind, placebo-controlled, multicenter Phase 2 study showed that BB3, administered as late as 24 hours after renal transplantation, met the primary and secondary endpoints of the study and improved outcome in patients with delayed graft function (DGF). BB3 has Orphan Drug and Fast Track designations from FDA, and is proceeding into Phase 3 in renal transplant patients with DGF in Angion’s GIFT (Graft Improvement Following Transplant) trial.
Help employers find you! Check out all the jobs and post your resume.
Two presentations are scheduled on Angion’s clinical stage investigational drug BB3, a proprietary small molecule with hepatocyte growth factor (HGF)-like therapeutic activities. In a presentation entitled “BB3, a Hepatocyte Growth Factor-like Small Molecule, Improves Outcome in Kidney Transplant Recipients with Delayed Graft Function," data from an interim analysis of a double-blind, placebo-controlled, multicenter Phase 2 study showed that BB3, administered as late as 24 hours after renal transplantation, met the primary and secondary endpoints of the study and improved outcome in patients with delayed graft function (DGF). BB3 has Orphan Drug and Fast Track designations from FDA, and is proceeding into Phase 3 in renal transplant patients with DGF in Angion’s GIFT (Graft Improvement Following Transplant) trial.
Help employers find you! Check out all the jobs and post your resume.